Active substance
Levobunolol
- SFDA 1
- US FDA 10
- US price lines 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BETAGAN 0.5% LIQUIFILM OPTH.SOLN. | 0.5 % | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 13.65 | NCE · Prescription | ALLERGAN PHARMACEUTICALS LTD | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| BETAGAN | 0.5% | solution/drops · ophthalmic | ALLERGAN | Prescription | 19 Dec 1985 |
| LEVOBUNOLOL HYDROCHLORIDE | 0.5% | solution/drops · ophthalmic | BAUSCH AND LOMB INC | Prescription | 4 Mar 1994 |
| BETAGAN | 0.25% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution/drops · ophthalmic | ALLERGAN | Discontinued | 28 Jun 1989 |
| LEVOBUNOLOL HYDROCHLORIDE | 0.25% | solution/drops · ophthalmic | BAUSCH AND LOMB | Discontinued | 4 Mar 1994 |
| LEVOBUNOLOL HYDROCHLORIDE | 0.5% | solution/drops · ophthalmic | CHARTWELL RX | Discontinued | 28 Oct 1996 |
| LEVOBUNOLOL HYDROCHLORIDE | 0.25% | solution/drops · ophthalmic | ALCON LABS INC | Discontinued | 28 Oct 1996 |
| AKBETA | 0.25% | solution/drops · ophthalmic | EPIC PHARMA LLC | Discontinued | 29 Oct 1996 |
| AKBETA | 0.5% | solution/drops · ophthalmic | EPIC PHARMA LLC | Discontinued | 29 Oct 1996 |
| LEVOBUNOLOL HYDROCHLORIDE | 0.25% | solution/drops · ophthalmic | APOTEX INC | Discontinued | 3 Aug 2000 |
| LEVOBUNOLOL HYDROCHLORIDE | 0.5% | solution/drops · ophthalmic | APOTEX INC | Discontinued | 3 Aug 2000 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LEVOBUNOLOL 0.5% EYE DROPS | $2.81863 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 22 Dec 2017 BETAGAN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.